Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in hea...
Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults
About this item
Full title
Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults
Author / Creator
Publisher
Netherlands: Elsevier Ltd
Journal title
Vaccine, 2022-11, Vol.40 (47), p.6740-6746
Language
English
Formats
Publication information
Publisher
Netherlands: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
Highlights•BPZE1 is a live, attenuated intranasal pertussis vaccine. •BPZE1 was not associated with clinically significant adverse events after vaccination. •BPZE1 induced both humoral and mucosal antibody responses after vaccination. •No prolonged shedding of BPZE1 was observed.
Alternative Titles
Full title
Safety and immunogenicity of live, attenuated intranasal Bordetella pertussis vaccine (BPZE1) in healthy adults
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2730671265
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2730671265
Other Identifiers
ISSN
0264-410X
E-ISSN
1873-2518
DOI
10.1016/j.vaccine.2022.09.075
